C136 - Multiple Sclerosis Therapy: Disease-modifying Treatment I

Event Time: Wednesday April 25, 2018 7:00 am to 9:00 am
Topic(s): MS and CNS Inflammatory Disease, Foundations in Clinical Neurology for APPs
Director(s): Scott Newsome DO, FAAN
Description: The use of disease-modifying treatments (DMTs) in MS is one of the most rapidly evolving therapeutic areas in neurology. As new and arguably more effective treatments have become available, decision-making in regard to MS DMTs has become much more complex for both neurologists and people with MS. This course will review the mechanisms of action and the risk-benefit ratios of the DMTs and delve into different treatment paradigms, risk mitigation strategies, sequencing considerations, and shared decision making. This program complements C147: Multiple Sclerosis Therapy: Disease-modifying Treatment II and C162: Multiple Sclerosis Therapy: Symptom Management, but covers independent topics.
Completion Message: Participants should be familiar with the indications and risks associated with approved disease-modifying agents in multiple sclerosis, and be better able to identify the appropriate patient populations for the newer agents.
CME Credits: 2
Core Competencies: Medical Knowledge, Patient Care

Ready to register for the 2019 AAN Annual Meeting?

Register Now

Related Courses